Sirion Therapeutics has begun enrolment for a Phase II trial of the compound fenretinide, as a treatment for geographic atrophy in patients with age-related macular degeneration.
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.